Recombinant Rat ARPC1B Protein Pre-coupled Magnetic Beads

• Cat.No.: ARPC1B-454R-B
• Product Overview: The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations.

Specification

• Source: HEK293
• Species: Rat
• Form: Solution
• Particle size: ~2 μm
• Beads Surface: Hydrophilic
• Capacity: > 200 pmol rabbit IgG/ mg beads
• Applications: Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification.
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions.
• Storage: 2-8℃. Do not to freeze thaw the Beads
• Concentration: 10mg beads/mL
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Arpc1b actin related protein 2/3 complex, subunit 1B [ Rattus norvegicus ]
• Official Symbol: ARPC1B
• Gene ID: 54227
• mRNA Refseq: NM_019289.2
• Protein Refseq: NP_062162.1
• UniProt ID: O88656

Reviews

02/18/2023

Their team of experts is highly knowledgeable, responsive, and dedicated to providing prompt solutions to any challenges I may face.

06/25/2021

By harnessing the power of the ARPC1B protein, I can harness its outstanding quality and tap into its potential to obtain dependable and meaningful findings.

11/01/2018

The ARPC1B protein is undoubtedly a superior choice, boasting extraordinary quality that guarantees it will fulfill all my experimental requirements.

Q&As

What diseases or disorders have been associated with dysregulation of the ARPC1B protein?

Dysregulation of the ARPC1B protein has been implicated in various types of cancer, including breast cancer and colorectal cancer. Additionally, mutations or deletions in the ARPC1B gene have been linked to developmental disorders such as intellectual disability and abnormal brain development.

How does the ARPC1B protein contribute to cancer progression?

The ARPC1B protein is involved in cancer progression by promoting cell motility, invasion, and metastasis. It functions within the Arp2/3 complex to facilitate the formation of actin-based protrusions that allow cancer cells to move and invade surrounding tissues.

Can modulation of the ARPC1B protein be considered as a potential therapeutic approach?

Modulation of the ARPC1B protein or its associated Arp2/3 complex could be a potential therapeutic approach for diseases involving aberrant actin cytoskeleton dynamics or cellular motility. However, further research is necessary to fully understand the functional consequences of ARPC1B dysregulation and to develop targeted therapeutic strategies.

Are there any ARPC1B inhibitors or potential therapeutic targets?

Currently, there are no specific inhibitors targeting the ARPC1B protein available for therapeutic use. However, as the Arp2/3 complex is an essential component of actin cytoskeleton regulation, inhibitors targeting the interaction between the complex and its activators may hold potential as anti-cancer agents.

What role does the ARPC1B protein play in brain development and intellectual disability?

ARPC1B is expressed in the developing brain and is crucial for proper neuronal migration and cortical development. Mutations or deletions in the ARPC1B gene have been associated with intellectual disability and cortical malformations, which are thought to result from disrupted actin dynamics impairing the normal development and function of neural circuits.

Are there any known drugs or therapeutic approaches targeting ARPC1B?

Currently, there are no specific drugs or therapeutic interventions targeting ARPC1B. However, as ARPC1B is involved in actin dynamics and cell migration, targeting other components of the actin cytoskeleton or signaling pathways that regulate actin polymerization may indirectly impact ARPC1B function and could be explored as potential therapeutic strategies.